Aarkstore - Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Aarkstore Enterprise
Scope
A snapshot of the global Market therapeutics scenario for Metastatic Breast Cancer.
A review of the marketed products under prescription for Metastatic Breast Cancer, regulatory
information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across
the globe.
Product profiles for marketed products for Metastatic Breast Cancer with complete description of
mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
Coverage of API Manufacturers for Metastatic Breast Cancer drugs in the United States, Europe and
Asian Regions with location details.
Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Metastatic
Breast Cancer drugs.
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Metastatic Breast
Cancer drugs.
Coverage of Metastatic Breast Cancer Phase III pipeline products featuring sections on product
description, mechanism of action, Chemical details and research & development progress.
Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
Key discontinued Marketed products.
Global Sales Figure from 2012-2016.
Reasons To Buy
Evaluate the marketing status and exclusivity details of Metastatic Breast Cancerkey products to exploit
opportunities for generic drug development opportunities.
Identify and understand important and diverse types of therapeutics under Phase III development for
Metastatic Breast Cancer.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry
details and exclusivity with respect to Metastatic Breast Cancer.
API intelligence over marketed drugs forMetastatic Breast Cancerand gaining primary intelligence over
active ingredients manufacturers across the globe.
API intelligence over leading Phase III Pipeline drugs.
Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to
enhance and expand business potential and scope.
Understanding the scope of the Phase III Drugs with nil regulatory filings.
Understanding the chemical route of synthesis of approved drugs for Metastatic Breast Cancer.
Uncovering opportunities in the rapidly growing US market.